Synovial Fibroblast 3.1: Secretion response of seven primary human synovial fibroblast samples from healthy and rheumatoid arthritis donors to a panel of 3 stimuli and 5 small molecule inhibitors (replicate 1 of 2) - Dataset (ID:20234)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
N2645 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 2 | IL-1B | 279.0 | 60 | |
N2645 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 2 | IL-1B | 307.0 | 68 | |
RA2708 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 2 | IL-1B | 337.0 | 71 | |
RA2708 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 2 | IL-1B | 274.0 | 68 | |
RA2159 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 2 | IL-1B | 362.5 | 70 | |
RA2159 | TNF-a | 100 | ng/mL | 2 | IL-1B | 362.0 | 69 | ||||
N2645 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 2 | IL-1B | 263.0 | 74 | |
N2645 | TNF-a | 100 | ng/mL | 2 | IL-1B | 336.0 | 75 | ||||
RA2708 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 2 | IL-1B | 310.0 | 59 | |
RA2708 | TNF-a | 100 | ng/mL | 2 | IL-1B | 349.0 | 47 | ||||
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 2 | IL-1B | 16.0 | 53 | |
RA2159 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 2 | IL-1B | 20.5 | 68 | |
N2645 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 2 | IL-1B | 15.0 | 91 | |
N2645 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 2 | IL-1B | 16.0 | 75 | |
RA2708 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 2 | IL-1B | 18.0 | 47 | |
RA2708 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 2 | IL-1B | 25.0 | 66 | |
RA2159 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 2 | IL-1B | 75.0 | 69 | |
RA2159 | IL-1 alpha | 100 | ng/mL | 2 | IL-1B | 68.0 | 68 | ||||
N2645 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 2 | IL-1B | 30.5 | 66 | |
N2645 | IL-1 alpha | 100 | ng/mL | 2 | IL-1B | 33.0 | 53 | ||||
RA2708 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 2 | IL-1B | 73.0 | 57 | |
RA2708 | IL-1 alpha | 100 | ng/mL | 2 | IL-1B | 68.5 | 64 | ||||
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 2 | IL-1B | 15.0 | 74 | |
RA2159 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 2 | IL-1B | 23.0 | 65 | |
N2645 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 2 | IL-1B | 15.0 | 85 |